According to the statement, patients will be able to receive the drug, developed jointly with Geropharm laboratories, once the clinical trials of the new drug have been completed.

Immune thrombocytopenia is a rare disease in which the immune system destroys platelets, causing increased bleeding. Many patients require long-term therapy.

The biosimilar GP40141, developed by Geropharm, is an analog of the original drug Nplate, but should be more affordable.

The study conducted by Russian specialists included 136 patients from 16 medical centers across the country.

After the tenth week of treatment, a positive response (normal platelet levels) was achieved in 78% of patients in the biosimilar group and 85% in the original group.

No significant differences in efficacy or safety were observed between the drugs.

The Russian biosimilar romiplostim has demonstrated its efficacy and safety in the final phase of clinical trials.

The drug already has a registration certificate and patients will be able to receive it through the state program.

Geropharm continues to study the long-term effects of the treatment.

abo/arm/mem/gf